Although antibodies are a critical element of the immune response, the role of antibody responses in cancer vaccines is still unknown. Carbohydrate antigens, which are directly or indirectly involved in most types of cancer vaccines, are a class of antigens that has been largely understudied but play a significant role in the immune response of cancer vaccines.
This invention involves the identification of serum biomarkers for cancer that target carbohydrate antigens. The biomarkers are specific sub-populations of serum antibodies present in the serum of patients that bind to various glycan and/or glycoprotein antigens, such as the Forssman antigen. This technology can be developed into a pioneering test, as no such test to monitor prognosis and efficacy of cancer vaccines currently exists in the market.
Clinical data has been obtained; validation studies are ongoing, preliminary results confirmed in two independent patient groups.
- Diagnostic and prognostic test to monitor the progression and long-term survival of cancer patients
- Predictive indicator of cancer patient's immune response to a cancer vaccine
- Indicator to monitor the efficacy of a cancer vaccine
- First diagnostic tool of its kind to monitor prognosis and efficacy of cancer vaccines.
Gildersleeve JC, et al. [PMID: 23063402]
- Foreign Filed: Australian - Patent Application
- Foreign Issued: EP - Patent Number 11749629.9